Bowman-Birk inhibitor (BBI), which is a soy-derived protease inhibitor, shows promise in the treatment of Multiple Sclerosis. In a recent study, BBI was administered in an animal model of multiple sclerosis and was shown to have a significant effect in prevention and suppression of inflammation. Dr. Abdolmohamad Rostami from Thomas Jefferson University, where the study was conducted, hopes that BBI will also be effective in treating MS patients.
Based on these positive results, a Phase I trial of BBI concentrate is planned in patients with MS as soon as funding can be secured.
SOURCE: Multiple Sclerosis, November 2006
All of us are looking for any and all options for helping those with Multiple Sclerosis and the Multiple Sclerosis for Dummies feature book at our Benzinger On Health website is no exception. I found this article interesting because it represents a new area of investigation and this treatment has had some success in animals, which is encouraging. There is so much to do, and I am prayerful that those in place to research and push forward will be supported and encouraged to not give up until every last case is helped.
